Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SCRI-CAR19v3 in Systemic Lupus Erythematosus: NCT06465147 Clinical Landscape Report 2026
16 October 2026
NCT06465147 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Medroxyprogesterone Acetate in Endometrioid Carcinoma: NCT06468215 Clinical Landscape Report 2026
16 October 2026
NCT06468215 clinical landscape for Endometrioid Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JNJ-88998377 in B-cell lymphoma refractory: NCT06470438 Clinical Landscape Report 2026
16 October 2026
NCT06470438 clinical landscape for B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enfortumab Vedotin-ejfv in Muscle Invasive Bladder Carcinoma: NCT06470282 Clinical Landscape Report 2026
16 October 2026
NCT06470282 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Tretinoin in Non-Hodgkin's lymphoma refractory: NCT06484920 Clinical Landscape Report 2026
16 October 2026
NCT06484920 clinical landscape for Non-Hodgkin's lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Poly ICLC in Locally Advanced Melanoma: NCT06472661 Clinical Landscape Report 2026
16 October 2026
NCT06472661 clinical landscape for Locally Advanced Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BMS-986463 in Uterine Serous Carcinoma: NCT06476808 Clinical Landscape Report 2026
16 October 2026
NCT06476808 clinical landscape for Uterine Serous Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lifileucel in Advanced Endometrial Carcinoma: NCT06481592 Clinical Landscape Report 2026
16 October 2026
NCT06481592 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in Endometrial Carcinoma: NCT06486441 Clinical Landscape Report 2026
16 October 2026
NCT06486441 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cenerimod in Systemic Lupus Erythematosus: NCT06475742 Clinical Landscape Report 2026
16 October 2026
NCT06475742 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AttIL12-T cell (MD Anderson) in Metastatic Soft Tissue Sarcoma: NCT06474676 Clinical Landscape Report 2026
16 October 2026
NCT06474676 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Benmelstobart in Endometrial Carcinoma: NCT06475599 Clinical Landscape Report 2026
16 October 2026
NCT06475599 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.